Kinfo
ClearPoint Neuro Inc. logo

ClearPoint Neuro Inc.

CLPTNASDAQHealthcare·US · USD
$15.23
+0.04 (+0.30%)
Prices as of August 13, 2026 · live

Price

Key statistics

Valuation
Market cap462.90M USD
Enterprise value468.05M USD
Trailing P/E-16.86
Forward P/E-13.23
PEG ratio-0.21
Price / sales10.56
Price / book41.47
Profitability
Gross margin61.67%
Operating margin-94.15%
Profit margin-81.76%
Return on assets-24.43%
Return on equity-226.52%
Income (TTM)
Revenue42.28M USD
Gross profit26.47M USD
EBITDA-28.21M USD
Net income-34.57M USD
Diluted EPS-$1.18
Rev. growth (YoY)18.10%
Balance sheet
Total cash29.36M USD
Total debt63.95M USD
Debt / equity593.41
Current ratio4.75
Book value / share$0.35
Cash flow (TTM)
Operating cash flow-30.18M USD
Levered free cash flow-14.05M USD
Shares & price
Shares outstanding30.50M
Float26.70M
Held by institutions50.02%
Beta1.27
50-day MA$15.34
200-day MA$13.92
52-week high$30.10
52-week low$8.27
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-03-0.29-0.38−31.03%2026-05-13-0.27-0.32−18.52%2026-03-17-0.20-0.27−35.00%2026-01-071.942.13+9.79%
About ClearPoint Neuro Inc.

ClearPoint Neuro Inc. is a medical device and technology company specializing in minimally invasive neurosurgical and spine procedures. The firm develops and commercializes MRI-guided platforms that enable precise navigation and controlled delivery of devices and therapies into the brain and spine. Its portfolio centers on the ClearPoint Neuro Navigation System, an integrated solution combining hardware, disposable instruments, and software for procedures such as deep brain stimulation, biopsies, laser ablation, and targeted infusion of cell, gene, and other biologic therapies. ClearPoint Neuro also offers ancillary products including SmartFrame access devices, delivery cannulas, and laser therapy systems, along with clinical and pre-clinical services that support therapy development and procedural execution. Serving healthcare and research centers across North America, Europe, Asia, and South America, the company plays a notable role in the healthcare and life sciences market by enabling high-precision interventions for complex neurological disorders under real-time MRI guidance. Founded in 1998 and headquartered in Solana Beach, California, ClearPoint Neuro operates today as a device, cell, and gene therapy-enabling platform company.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Joseph Michael Burnett
Employees
160
Headquarters
Solana Beach, CA, United States

Frequently asked questions about ClearPoint Neuro Inc.